Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linifanib in advanced renal cell carcinoma post-sunitinib
NCT00486538Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2007
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of linifanib in renal cell carcinoma (RCC), sponsored by AbbVie Inc. Primary endpoint: Objective Response Rate at 2 years. Started Jun 2007; status: completed.
02
Drugs
linifanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00486538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00486538.